Skip to main content
SpringerLink
Log in

Anti-Idiotypic Antibodies as Potential Viral Vaccines

  • Chapter
Anti-Idiotypic Vaccines

Part of the book series: Progress in Vaccinology ((VACCINOLOGY,volume 3))

  • 30 Accesses

Abstract

Although conventional vaccines have been demonstrated to be highly effective in stimulating protective immunity against a wide range of microorganisms, there are still instances in which suitable vaccines are lacking. For example, the inability to culture large quantities of numerous protozoal pathogens in vitro has prevented the development of conventional vaccines for these organisms. Other obstacles to the development of conventional vaccines include the poor humoral response of infants under the age of 2 years to certain polysaccharide antigens present on encapsulated bacteria (i.e., Neisseria meningitidis, Vibrio cholera, and Hemophilus influenzae) (1, 2). Also, the recent spread of the human immunodeficiency virus type 1 (HIV-1) and its possible origin and evolution from viruses isolated from nonhuman primate species has pointed up the necessity of developing a vaccine that is incapable of reverting to a virulent form. These obstacles have led to the development of a new generation of vaccines. Recombinant proteins, synthetic peptides, and anti-idiotypic antibodies represent relatively new technologies that are currently being examined for their potential use in stimulating immunity against various microorganisms (reviewed in 3 and 4). This report will review studies from this laboratory that examine the potential use of anti-Idiotype to generate immunity to HIV-1 and hepatitis B virus (HBV).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Pincus DJ, Morrison D, Andrews C, Lawrence E, Sell SH, Wright PF: Age-related response to two Haemophilus influenzae type b vaccines. J Pediatr 1982; 100:197–201.

    PubMed  CAS  Google Scholar 

  2. Parke JC Jr, Schneerson R, Robbins JB, Schlesselman JJ: Interim report of a controlled field trial immunization with capsular polysaccharides of Haemophilus influenzae type b and group C Neisseria meningitidis in Mecklenburg County, North Carolina (March 1974-March 1976). J Infect Dis 1977; (suppl) 136:s51–s56.

    Google Scholar 

  3. Arnon R: Peptides as immunogens: Prospects for synthetic vaccines. Curr Top Microbiol Immunol 1986; 130:1–12.

    PubMed  CAS  Google Scholar 

  4. Hkrnaux JR: Idiotypic vaccines and infectious diseases. Infect Immun 1988; 56:1407–1413.

    PubMed  CAS  Google Scholar 

  5. Jerne NK: Toward a network theory of the immune system. Ann Immunol (Paris) 1974; 125C:373–389.

    CAS  Google Scholar 

  6. Bona CA, Pernis B: Idiotypic networks. In: Paul WE, ed: Fundamental Immunology. New York: Raven Press; 1984; 577–592.

    Google Scholar 

  7. Bona CA ed: Biological Applications of Anti-Idiotypes, II. Boca Raton, Fla: CRC Press; 1988.

    Google Scholar 

  8. Jerne NK, Roland J, Cazenave P-A: Recurrent idiotopes and internal images. EMBO J 1982; l(2) :243–247.

    Google Scholar 

  9. Bona CA, Kohler H: Anti-idiotypic antibodies and internal images. In: Venter JC, Fräser CM, Linstrom J, eds: Monoclonal and Anti-Idiotypic Antibodies: Probes for Receptor Structure and Function. Receptor Biochemistry and Methodology Series, vol. 4. New York; Alan R. Liss; 1984: p 141–149.

    Google Scholar 

  10. Bruck C, Co MS, Slaoui M, et al: Nucleic acid sequence of an internal image-bearing monoclonal anti-idiotype and its comparison to the sequence of the external antigen. Proc Natl Acad Sci USA 1986; 83:6578–6582.

    PubMed  CAS  Google Scholar 

  11. Bona CA, Finley S, Waters S, Kunkel HG: Anti-immunoglobulin antibodies. III. Properties of sequential anti-idiotypic antibodies to heterologous anti-γ globulins. Detection of reactivity of anti-idiotype antibodies with epitopes of Fc fragments (homobodies) and epitopes and idiotopes (epibodies). J Exp Med 1982; 156:986–999.

    PubMed  CAS  Google Scholar 

  12. Augustin A, Cosenza A: Expression of new idiotypeslollowing neonatal idiotypic suppression of a dominant clone. Eur J Immunol 1976; 6:497–501.

    PubMed  CAS  Google Scholar 

  13. Bona C, Stein KE, Lieberman R, Paul WE: Direct and indirect suppression induced by anti-idiotype antibody in the insulin-bacterial levan antigenic system. Mol Immunol 1979; 16:1093–1101.

    PubMed  CAS  Google Scholar 

  14. Sharpe AH, Gaulton GN, McDade KK, Fields BN, Greene MI: Syngeneic monoclonal antiidiotype can induce cellular immunity to reovirus. J Exp Med 1984; 160:1195–1205.

    PubMed  CAS  Google Scholar 

  15. Nepom GT, Nelson KA, Holbeck SL, Hellström I, Hellström KE: Induction of immunity to a human tumor marker by in vivo administration of anti-idiotypic antibodies in mice. Proc Natl Acad Sci USA 1984; 81:2864–2867.

    PubMed  CAS  Google Scholar 

  16. Forstrom JW, Nelson KA, Nepom GT, Hellström I, Hellström KE: Immunization to a syngeneic sarcoma by a monoclonal auto-anti-idiotypic antibody. Nature 1983; 303:627–629.

    PubMed  CAS  Google Scholar 

  17. Lee VK, Harriott TG, Kuchroo VK, Halliday WJ, Hellström I, Hellström KE: Monoclonal antiidiotypic antibodies related to a murine oncofetal bladder tumor antigen induce specific cell-mediated tumor immunity. Proc Natl Acad Sci USA 1985; 82:6286–6290.

    PubMed  CAS  Google Scholar 

  18. Raychaudhuri S, Saeki Y, Chen JJ, Iribe H, Fuji H, Kohler H: Tumor-specific idiotype vaccines. II. Analysis of the tumor-related network response induced by the tumor and by internal image antigens (Ablß). J Immunol 1987; 139:271–278.

    PubMed  CAS  Google Scholar 

  19. Gaulton GN, Sharpe AH, Chang DW, Fields BN, Greene MI: Syngeneic monoclonal internal image anti-idiotopes as prophylactic vaccines. J Immunol 1986; 137:2930–2936.

    PubMed  CAS  Google Scholar 

  20. Zhou EM, Chanh TC, Dreesman GR, Kanda P, Kennedy RC: Immune response to human immunodeficiency virus. In vivo administration of antiidiotype induces an anti-gpl60 response specific for a synthetic peptide. J Immunol 1987; 139:2950–2956.

    PubMed  CAS  Google Scholar 

  21. Dalgleish AG, Thomson BJ, Chanh TC, Malkovsky M, Kennedy RC: Neutralisation of HIV isolates by anti-idiotypic antibodies which mimic the T4 (CD4) epitope: A potential AIDS vaccine. Lancet 1987; 2:1047–1050.

    PubMed  CAS  Google Scholar 

  22. Kennedy RC, Eichberg JW, Lanford RE, Dreesman GR: Anti-idiotypic antibody vaccine for type B viral hepatitis in chimpanzees. Science 1986; 232:220–223.

    PubMed  CAS  Google Scholar 

  23. Kennedy RC, Melnick JL, Dreesman GR: Antibody to hepatitis B virus induced by injecting antibodies to the idiotype. Science 1984; 223:930–931.

    PubMed  CAS  Google Scholar 

  24. Schick MR, Dreesman GR, Kennedy RC: Induction of an anti-hepatitis B surface antigen response in mice by noninternal image (Ab2α) anti-idiotypic antibodies. J Immunol 1987; 138:3419–3425.

    PubMed  CAS  Google Scholar 

  25. Thanavala YM, Brown SE, Howard CR, Roitt IM, Steward MW: A surrogate hepatitis B virus antigenic epitope represented by a synthetic peptide and an internal image anti-idiotypic antibody. J Exp Med 1986; 164:227–236.

    PubMed  CAS  Google Scholar 

  26. Colucci G, Beazer Y, Waksal S: Interactions between HBV and polymeric human serum albumin. II. Development of syngeneic monoclonal anti-anti-idiotypes which mimic hepatitis B surface antigen in the induction of immune responsiveness. Eur J Immunol 1987; 17:371–374.

    PubMed  CAS  Google Scholar 

  27. Keay S, Rasmussen L, Merigan TC: Syngeneic monoclonal anti-idiotype antibodies that bear the internal image of a human cytomegalovirus neutralization epitope. J Immunol 1988; 140:944–948.

    PubMed  CAS  Google Scholar 

  28. Ertl HCJ, Finberg RW: Sendai virus-specific T-cell clones: Induction of cytolytic T-eells by an anti-idiotypic antibody directed against a helper T-cell clone. Proc Natl Acad Sci USA 1984; 81:2850–2854.

    PubMed  CAS  Google Scholar 

  29. Ertl HCJ, Homans E, Tournas S, Finberg RW: Sendai virus-specific T cell clones. V. Induction of a virus-specific response by antiidiotypic antibodies directed against a T helper cell clone. J Exp Med 1984; 159:1778–1783.

    PubMed  CAS  Google Scholar 

  30. Reagan KJ, Wunner WH, Wiktor TJ, Koprowski H: Anti-idiotypic antibodies induce neutralizing antibodies to rabies virus glycoprotein. J Virol 1983; 48:660–666.

    PubMed  CAS  Google Scholar 

  31. Uytdehaag FGCM, Osterhaus ADME: Induction of neutralizing antibody in mice against poliovirus type II with monoclonal anti-idiotypic antibody. J Immunol 1985; 134:1225–1229.

    PubMed  CAS  Google Scholar 

  32. Gell PGH, Moss PAH: Production of cell-mediated immune response to herpes simplex virus by immunization with anti-idiotypic heteroantisera. J Gen Virol 1985; 66:1801–1804.

    PubMed  Google Scholar 

  33. Lathey JL, Courtney RJ, Rouse BT: Production, binding characteristics, and immunogenicity of heterologous anti-idiotypic antibody to herpes simplex virus glycoprotein C. Viral Immunol 1987; 1:13–24.

    PubMed  CAS  Google Scholar 

  34. Mayer R, Ioannides C, Moran T, Johansson B, Bona C: Effect of syngeneic anti-idiotypic antibody on influenza virus neuraminidase antibody response. Viral Immunol 1987; 1:121–134.

    PubMed  CAS  Google Scholar 

  35. Tanaka M, Sasaki N, Seto A: Induction of antibodies against Newcastle disease virus with syngeneic anti-idiotype antibodies in mice. Microbiol Immunol 1986; 30:323–331.

    PubMed  CAS  Google Scholar 

  36. Paque RE, Miller R: Modulation of murine Coxsackievirus-induced myocarditis utilizing anti-idiotypes. Viral Immunol 1987; 1:207–224.

    PubMed  Google Scholar 

  37. Ludwig DS, Finkelstein RA, Karu AE, Dallas WS, Ashby ER, Schoolnik GK: Anti-idiotypic antibodies as probes of protein active sites: Application to cholera tein subunit B. Proc Natl Acad Sci USA 1987; 84:3673–3677.

    PubMed  CAS  Google Scholar 

  38. Chanh TC, Huot RI, Schick MR, Hewetson JF: Anti-idiotypic antibodies against a monoclonal antibody specific for the trichothecene mycotoxin T-2. Toxicol Appl Pharmacol 1989; 100:201–207.

    PubMed  CAS  Google Scholar 

  39. Hiernaux J, Bona C, Baker PJ: Neonatal treatment with low doses of anti- idiotypic leads to the expression of a silent clone. J Exp Med 1981; 153:1004–1008.

    PubMed  CAS  Google Scholar 

  40. Rubinstein LJ, Yeh M, Bona CA: Idiotype-anti-idiotype network. II. Activation of silent clones by treatment at birth with idiotypes is associated with the expansion of idiotype-specific helper T cells. J Exp Med 1982; 156:506–521.

    PubMed  CAS  Google Scholar 

  41. Marvel J, Tassignon J, Brait M, et al: The influence of Vk gene polymorphism on the induction of silent idiotypes in the arsonate system. Mol Immunol 1987; 24:463–469.

    PubMed  CAS  Google Scholar 

  42. Francotte M, Urbain J: Induction of anti-tobacco mosaic virus antibodies in mice by rabbit antiidiotypic antibodies. J Exp Med 1984; 160:1485–1494.

    PubMed  CAS  Google Scholar 

  43. Bona CA, Heber-Katz E, Paul WE: Idiotype-anti-idiotype regulation. Immunization with a levan-binding myeloma protein leads to the appearance of auto-anti-(anti-idiotype) antibodies and to the activation of silent clones. J Exp Med 1981; 153:951–967.

    PubMed  CAS  Google Scholar 

  44. Gottlieb MS, Schroff R, Schanker HM, et al: Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men. Evidence of a new acquired cellular immunodeficiency. N Engl J Med 1981; 305:1425–1431.

    PubMed  CAS  Google Scholar 

  45. Masur H, Michelis MA, Greene JB, et al: An outbreak of community-acquired Pneumocystis carinii penumonia. Initial manifestation of cellular immune dysfunction. N Engl J Med 1981; 305:1431–1438.

    PubMed  CAS  Google Scholar 

  46. Siegal FP, Lopez C, Hammer GS, et al: Severe acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesions. N Engl J Med 1981; 305:1439–1444.

    PubMed  CAS  Google Scholar 

  47. Wain-Hobson S, Sonigo P, Danos O, Cole S, Alizon M: Nucleotide sequence of the AIDS virus, LAV. Cell 1985; 40:9–17.

    PubMed  CAS  Google Scholar 

  48. Ratner L, Haseltine W, Patarca R, et al: Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature 1985; 313:277–284.

    PubMed  CAS  Google Scholar 

  49. Muesing MA, Smith DH, Cabradilla CD, Benton CV, Laskey LA, Capon DJ: Nucleic acid structure and expression of the human AIDS/lymphadenopathy retrovirus. Nature 1985; 313:450–458.

    PubMed  CAS  Google Scholar 

  50. Sanchez-Pescador R, Power MD, Barr PJ, et al: Nucleotide sequence and expression of an AIDS-associated retrovirus (ARV-2). Science 1985; 227:484–492.

    PubMed  CAS  Google Scholar 

  51. Swain SL: T cell subsets and the recognition of MHC class. Immunol Rev 1983; 74:129–142.

    PubMed  CAS  Google Scholar 

  52. Krensky AM, Reiss CS, Mier JW, Strominger JL, Burakoff SJ: Long-term human cytolytic T-cell lines allospecific for HLA-DR6 antigen are OKT4+. Proc Natl Acad Sci USA 1982; 79:2365–2369.

    PubMed  CAS  Google Scholar 

  53. Spits H, Borst J, Terhorst C, de Vries JE: The role of T cell differentiation markers in antigen-specific and lectin-dependent cellular cytotoxicity mediated by T8+ and T4+ human cytotoxic T cell clones directed at class I and class II MHC antigens. J Immunol 1982; 129:1563–1569.

    PubMed  CAS  Google Scholar 

  54. Meuer SC, Schlossman SF, Reinherz EL: Clonal analysis of human cytotoxic T lymphocytes: T4+ and T8+ effector T cells recognize products of different major histocompatibility complex regions. Proc Natl Acad Sci USA 1982; 79:4395–4399.

    PubMed  CAS  Google Scholar 

  55. Wilde DB, Marrack P, Kappler J, Dialynas DP, Fitch FW: Evidence implicating L3T4 in class II MHC antigen reactivity; monoclonal antibody GK1.5 (anti-L3T4) blocks class II MHC antigen-specific proliferation release of lymphokines, and binding by cloned murine helper T lymphocyte lines. J Immunol 1983; 131:2178–2183.

    PubMed  CAS  Google Scholar 

  56. Swain SL, Dialynas DP, Fitch FW, English M: Monoclonal antibody to L3T4 blocks the function of T cells specific for class 2 major histocompatibility complex antigens. J Immunol 1984; 132:1118–1123.

    PubMed  CAS  Google Scholar 

  57. Gay D, Maddon P, Sekaly R, et al: Functional interaction between human T-cell protein CD4 and the major histocompatibility complex HLA-DR antigen. Nature 1987; 328:626–629.

    PubMed  CAS  Google Scholar 

  58. Doyle C, Strominger JL: Interaction between CD4 and class II MHC molecules mediates cell adhesion. Nature 1987; 330:256–259.

    PubMed  CAS  Google Scholar 

  59. Reinherz EL, Schlossman SF: The differentiation and function of human T lymphocytes. Cell 1980; 19:821–827.

    PubMed  CAS  Google Scholar 

  60. Dialynas DP, Quan ZS, Wall KA, et al: Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: Similarity of L3T4 to the human Leu-3/T4 molecule. J Immunol 1983; 131:2445–2451.

    PubMed  CAS  Google Scholar 

  61. Marrack P, Endres R, Shimonkevitz R, et al: The major histocompatibility complex-restricted antigen receptor on T cells. II. Role of the L3T4 product. J Exp Med 1983; 158:1077–1091.

    PubMed  CAS  Google Scholar 

  62. Maddon PJ, Littman DR, Godfrey M, Maddon DE, Chess L, Axel R: The isolation and nucleotide sequence of a cDNA encoding the T cell surface protein T4: A new member of the immunoglobulin gene family. Cell 1985; 42:93–104.

    PubMed  CAS  Google Scholar 

  63. Maddon PJ, Molineaux SM, Maddon DE, et al: Structure and expression of the human and mouse T4 genes. Proc Natl Acad Sci USA 1987; 84:9155–9159.

    PubMed  CAS  Google Scholar 

  64. Clayton LK, Hussey RE, Steinbrich R, Ramachandran H, Husain Y, Reinherz EL: Substitution of murine for human CD4 residues identifies amino acids critical for HIV-gp120 binding. Nature 1988; 335:363–366.

    PubMed  CAS  Google Scholar 

  65. Classon BJ, Tsagaratos J, McKenzie IFC, Walker ID: Partial primary structure of the T4 antigens of mouse and sheep: Assignment of intrachain disulfide bonds. Proc Natl Acad Sci USA 1986; 83:4499–4503.

    PubMed  CAS  Google Scholar 

  66. Clark SJ, Jefferies WA, Barclay AN, Gagnon J, Williams AF: Peptide and nucleotide sequences of rat CD4 (w3/25) antigen: Evidence for derivation from a structure with four immunoglobulin-related domains. Proc Natl Acad Sci USA 1987; 84:1649–1653.

    PubMed  CAS  Google Scholar 

  67. Littman DR, Gettner SN: Unusual intron in the immunoglobulin domain of the newly isolated murine CD4 (L3T4) gene. Nature 1987; 325:453–455.

    PubMed  CAS  Google Scholar 

  68. Benn S, Rutledge R, Folks T, et al: Genomic heterogeneity of AIDS retroviral isolates from North America and Zaire. Science 1985; 230:949–951.

    PubMed  CAS  Google Scholar 

  69. Sonigo P, Alizon M, Staskus K, et al: Nucleotide sequence of the visna lentivirus. Relationship to the AIDS virus. Cell 1985; 42:369–382.

    PubMed  CAS  Google Scholar 

  70. Myers G, Josephs SF, Berzofsky JA, Rabson AB, Smith TF, Wong-Staal F (eds): Human retroviruses and AIDS, 1989. A compilation and analysis of nucleic acid and amino acid sequences. Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, New Mexico, 1989.

    Google Scholar 

  71. Wong-Staal F, Shaw GM, Hahn BH, et al: Genomic diversity of human T-lymphotropic virus type III (HTLV-III). Science 1985; 229:759–762.

    PubMed  CAS  Google Scholar 

  72. Alizon M, Wain-Hobson S, Montagnier L, Sonigo P: Genetic variability of the AIDS virus: Nucleotide sequence analysis of two isolates from African patients. Cell 1986; 46:63–74.

    PubMed  CAS  Google Scholar 

  73. Weiss RA, Clapham PR, Weber JN, Dalgleish AG, Laskey LA, Berman PW: Variable and conserved neutralization antigens of human immunodeficiency virus. Nature 1986; 324:572–575.

    PubMed  CAS  Google Scholar 

  74. Saag MS, Hahn BH, Gibbons J, et al: Extensive variation of human immunodeficiency virus type-1 in vivo. Nature 1988; 334:440–444.

    PubMed  CAS  Google Scholar 

  75. Fisher AG, Ensoli B, Looney D, et al: Biologically divergent molecular variants within a single HIV-1 isolate. Nature 1988; 334:444–447.

    PubMed  CAS  Google Scholar 

  76. Fauci AS: The human immunodeficiency virus: Infectivity and mechanisms of pathogenesis. Science 1988; 239:617–622.

    PubMed  CAS  Google Scholar 

  77. Halstead SB, O’Rourke EJ: Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody. J Exp Med 1977; 146:201–217.

    PubMed  CAS  Google Scholar 

  78. Robinson WE Jr, Montefiori DC, Mitchell WM: Antibody dependent enhancement of human immunodeficiency virus type 1 infection. Lancet 1988; 1:790–794.

    PubMed  Google Scholar 

  79. Takeda A, Tuazon CU, Ennis FA: Antibody-enhanced infection by HIV-1 via Fc receptor-mediated entry. Science 1988; 242:580–583.

    PubMed  CAS  Google Scholar 

  80. Dalgleish AG: Human trials of AIDS vaccines: Novel means of passive and active immunotherapy. AIDS 2 1988; (suppl 1):S129–S131.

    PubMed  Google Scholar 

  81. Snart RS: Human trials of experimental AIDS vaccines: Recombinant envelope proteins. AIDS 2 1988; (suppl 1):S107–111.

    PubMed  Google Scholar 

  82. Kennedy RC, Chanh TC: Perspectives on developing anti-idiotype based vaccines for controlling HIV infection. AIDS 2 1988; (suppl 1):S119-S127.

    PubMed  Google Scholar 

  83. Smith DH, Byrn RA, Marsters SA, Gregory T, Groopman JE, Capon DJ: Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen. Science 1987; 238:1704–1707.

    PubMed  CAS  Google Scholar 

  84. Fisher RA, Bertonis JM, Meier W, et al: HIV infection is blocked in vitro by recombinant soluble CD4. Nature 1988; 331:76–78.

    PubMed  CAS  Google Scholar 

  85. Hussey RE, Richardson NE, Kowalski M, et al: A soluble CD4 protein selectively inhibits HIV replication and syncytium formation. Nature 1988; 331:78–81.

    PubMed  CAS  Google Scholar 

  86. Deen KC, McDougal JS, Inacker R, et al: A soluble form of CD4 (T4) protein inhibits AIDS virus infection. Nature 1988; 331:82–84.

    PubMed  CAS  Google Scholar 

  87. Traunecker A, Luke W, Karjalainen K: Soluble CD4 molecules neutralize human immunodeficiency virus type 1. Nature 1988; 331:84–86.

    PubMed  CAS  Google Scholar 

  88. Sattentau QJ, Dalgleish AG, Weiss RA, Beverley PCL: Epitopes of the CD4 antigen and HIV infection. Science 1986; 234:1120–1123.

    PubMed  CAS  Google Scholar 

  89. Chanh TC, Dreesman GR, Kennedy RC: Monoclonal anti-idiotypic antibody mimics the CD4 receptor and binds human immunodeficiency virus. Proc Natl Acad Sci USA 1987; 84:3891–3895.

    PubMed  CAS  Google Scholar 

  90. Beasley RP: Hepatitis B virus as the etiologic agent in hepato-cellular carcinoma: Epidemiologic considerations. Hepatology 1982; 2:21–26.

    Google Scholar 

  91. McAuliffe VJ, Purcell RH, Gerin JL: Type B hepatitis: A review of current prospects for a safe and effective vaccine. Rev Infect Dis 1980; 2:470–492.

    PubMed  CAS  Google Scholar 

  92. Levene C, Blumberg BS: Additional specificities of Australia antigen and the possible identification of hepatitis carriers. Nature 1969; 221:195–196.

    PubMed  CAS  Google Scholar 

  93. Le Bouvier GL: The heterogeneity of Australia antigen. J Infect Dis 1971; 123:671–675.

    PubMed  Google Scholar 

  94. Bancroft WH, Mundon FK, Russell PK: Detection of additional antigenic determinants of hepatitis B antigen. J Immunol 1972; 109:842–848.

    PubMed  CAS  Google Scholar 

  95. Szmuness W, Stevens CE, Harley EJ, et al: Hepatitis B vaccine. Demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med 1980; 303:833–841.

    PubMed  CAS  Google Scholar 

  96. Kennedy RC, Dreesman GR: Common idiotypic determinant associated with human antibodies to hepatitis B surface antigen. J Immunol 1983; 130:385–389.

    PubMed  CAS  Google Scholar 

  97. Kennedy RC, Sanchez Y, Ionescu-Matiu I, Melnick JL, Dreesman GR: A common human anti-hepatitis B surface antigen idiotype is associated with the group a conformation-dependent antigenic determinant. Virology 1982; 122:219.

    PubMed  CAS  Google Scholar 

  98. Kennedy RC, Dreesman GR, Sparrow JT, et al: Inhibition of a common human anti-hepatitis B surface antigen idiotype by a cyclic synthetic peptide. J Virol 1983; 46:653–655.

    PubMed  CAS  Google Scholar 

  99. Kennedy RC, Ionescu-Matiu I, Sanchez Y, Dreesman GR: Detection of interspecies indiotypic cross-reactions associated with antibodies to hepatitis B surface antigen. Eur J Immuno 1983; 13:232–235.

    CAS  Google Scholar 

  100. Kennedy RC, Adler-Storthz K, Henkel RD, Sanchez Y, Melnick JL, Dreesman GR: Immune response to hepatitis B surface antigen: Enhancement by prior injection of antibodies to the idiotype. Science 1983; 221:853–855.

    PubMed  CAS  Google Scholar 

  101. Kennedy RC, Sparrow JT, Sanchez Y, Melnick JL, Dreesman GR: Enhancement of viral hepatitis B antibody (anti-HBS) response to a synthetic cyclic peptide by priming with anti-idiotype antibodies. Virology 1984; 136:247–252.

    PubMed  CAS  Google Scholar 

  102. Kennedy RC, Dreesman GR: Enhancement of the immune response to hepatitis B surface antigen. In vivo administration to antiidiotype induces anti-HB that expresses a similar idiotype. J Exp Med 1984; 159:655–665.

    PubMed  CAS  Google Scholar 

  103. Kennedy RC, Eichberg JW, Dreesman GR: Lack of genetic restriction by i potential anti-idiotype vaccine type B viral hepatitis. Virology 1986; 148:369–374.

    PubMed  CAS  Google Scholar 

  104. Rajewsky K, Takemori T: Genetics, expression, and function of idiotypes. Ann Rev Immunol 1983; 1:569–607.

    CAS  Google Scholar 

  105. Peltola H, Kayhty H, Sivonen A, Makela PH: Haemophilus influenzae type B capsular polysaccharide vaccine in children: A double-blind field study of 100,000 vaccines 3 months to 5 years of age in Finland. Pediatrics 1911; 60:730–737.

    Google Scholar 

  106. Peltola H, Kayhty H, Virtanen M, Makela PH: Prevention of Haemophilus influenzae type B bacteremic infections with the capsular polysaccharide vaccine. N Engl J Med 1984; 310:1561–1566.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Ronald Q. Warren
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ronald C. Kennedy
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. 28, Rue du Dr. Roux, F-75724, Paris Cedex 15, France

    P.-A. Cazenave

Rights and permissions

Reprints and permissions

Copyright information

© 1991 Springer-Verlag New York Inc.

About this chapter

Cite this chapter

Warren, R.Q., Kennedy, R.C. (1991). Anti-Idiotypic Antibodies as Potential Viral Vaccines. In: Cazenave, PA. (eds) Anti-Idiotypic Vaccines. Progress in Vaccinology, vol 3. Springer, New York, NY. https://doi.org/10.1007/978-1-4612-2992-6_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-4612-2992-6_7

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4612-7750-7

  • Online ISBN: 978-1-4612-2992-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation